Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Vaxcyte, Inc. is a clinical-stage biotechnology company focused on the development of next-generation vaccines to prevent serious bacterial infectious diseases. The company operates within the biotechnology and vaccines industries, with a primary emphasis on pneumococcal disease, which can cause pneumonia, meningitis, and bloodstream infections. Vaxcyte does not currently generate commercial product revenue and is primarily funded through equity financing to support research and development activities.
The company’s core strategy is centered on developing carrier-sparing conjugate vaccines, a differentiated approach intended to enable broader serotype coverage compared with existing pneumococcal vaccines. Vaxcyte was founded in 2013 under the name SutroVax, originating as a spinout from Sutro Biopharma, Inc., and rebranded as Vaxcyte in 2019. Since then, it has advanced multiple pneumococcal vaccine candidates into clinical development, positioning itself as a potential competitor to established vaccine manufacturers through higher-valency vaccine designs.
Business Operations
Vaxcyte’s operations are organized around the research and clinical development of its pneumococcal conjugate vaccine candidates, primarily VAX‑24 and VAX‑31, which target 24 and 31 pneumococcal serotypes, respectively. These programs represent the company’s principal business activities and are intended to address both adult and pediatric pneumococcal disease markets. Revenue generation is not yet established, as all candidates remain in clinical development stages.
The company conducts its research and development activities primarily in the United States and relies on a combination of internal scientific teams and third-party contractors for clinical trials, manufacturing, and regulatory support. Vaxcyte controls proprietary technology related to carrier-sparing conjugation and maintains manufacturing relationships to support clinical supply. As of publicly available disclosures, the company does not report material joint ventures and operates without commercial subsidiaries generating independent revenue.
Strategic Position & Investments
Vaxcyte’s strategic direction is focused on advancing its high-valency pneumococcal vaccine candidates through clinical trials with the goal of regulatory approval and commercialization. Growth initiatives are centered on expanding clinical data, progressing late-stage trials, and preparing for potential large-scale manufacturing. The company’s pipeline strategy emphasizes differentiation through broader serotype coverage and simplified manufacturing relative to existing pneumococcal conjugate vaccines.
The company has not disclosed significant acquisitions and primarily invests capital into internal research and development rather than external portfolio investments. Its notable subsidiaries include Vaxcyte UK Limited, which supports international operations. Emerging areas of focus include the application of its conjugation platform to additional bacterial pathogens, although details beyond pneumococcal disease remain limited in public disclosures.
Geographic Footprint
Vaxcyte is headquartered in San Carlos, California, within the United States, which serves as the center for its executive leadership and core research operations. The company’s activities are primarily U.S.-based, reflecting its current clinical-stage status and concentration on development rather than commercial distribution.
Internationally, Vaxcyte maintains a limited operational presence, including activities in Europe through its UK subsidiary, largely related to clinical development and regulatory coordination. While its vaccines are intended for global markets, particularly in regions with high pneumococcal disease burden, the company does not yet have a broad commercial or manufacturing footprint outside North America.
Leadership & Governance
Vaxcyte is led by an executive team with experience in vaccine development, biotechnology, and pharmaceutical commercialization. The leadership emphasizes a science-driven culture focused on addressing unmet medical needs in infectious disease prevention through innovative vaccine design.
Key executives include:
- Grant Pickering – Chief Executive Officer
- James Wassil – Chief Financial Officer
- Andrew Allen – Chief Scientific Officer
- Jim Wassil – Chief Financial Officer
Information regarding leadership philosophy and governance practices is primarily articulated through company communications and public filings, which emphasize disciplined capital allocation, rigorous clinical development, and long-term value creation. Some executive role details may vary slightly across public sources; where discrepancies exist, data is inconclusive based on available public sources.